Product description

The Invesco NASDAQ Biotech UCITS ETF Acc aims to provide the performance of the NASDAQ Biotechnology Index, after fees. The index comprises biotechnology and pharmaceuticals companies (as defined by ICB) listed on the NASDAQ Stock Market.  Stocks are filtered to meet minimum market capitalisation and liquidity requirements. They are then weighted by modified market capitalisation: the largest five constituents are capped at 8%; the remaining constituents are capped at 4%. The index is rebalanced quarterly and reviewed annually in December.

Key information

Bloomberg ticker SBIO LN
Benchmark BBG ticker XNBI
Management fee 0.40%
Swap fee 0.00%
NAV (21 Jun 2021) $51.35
AUM $739,427,178
Base currency USD
Umbrella AUM (21 Jun 2021) $28,590,437,540

ESG Profile

(Index 21 Jun 2021)

ESG Rating (AAA-CCC) A
Quality Score (0-10) 6.17
Carbon Intensity 19.94

Source: MSCI ESG Research. For more information on the ESG profile, see the ESG section on this product page. Carbon intensity is the weighted average carbon intensity (Tons CO2e/$million sales).

Key risks

Counterparty risk:  Other financial institutions provide services such as safekeeping of assets or as a counterparty to financial contracts such as derivatives. The Fund is exposed to the risk of bankruptcy, or any other type of default of the counterparty related to any trading transaction entered into by the Fund.

Risk of using derivatives:  in order to reach its investment objective, the Fund enters into swap agreements which provide the performance of the Reference Index, and may imply a range of risks which could lead to an adjustment or even the early termination of the swap agreement.

Liquidity on secondary market risk:  Lower liquidity means there are insufficient buyers or sellers to allow the Fund to sell or buy investments readily. On-exchange liquidity may be limited due to Reference Index suspension, a decision by one of the relevant stock exchanges, or a breach by the market maker of respective stock exchange requirements and guidelines. 



The performance information on this web page refers to past performance. Past performance is not a reliable indicator of future returns.

The data shown on this page is not real-time, i.e. it may be delayed due to mandatory requirements of the data provider. As a consequence, the price of the product linked to a specific underlying you are quoted by your broker or intermediary may substantially differ from the price of the product that you would expect on the basis of the data displayed on this site. Invesco accepts no responsibility for loss, however caused, resulting from errors in this data.

ETF performance is in the fund’s base currency, includes dividends, reinvested. ETF performance is Net Asset Value after management fees and other ETF costs but does not consider any commissions or custody fees payable when buying, holding or selling the ETF. The ETF does not charge entry or exit fees. Data: Invesco.